RxDoctor Payments Data

Steven Petrovas, MD

Pain Medicine · Grand Rapids, MINPI 1568775443

Payments from drug & device makers

$1,927in general payments, 2019–2025

Across 55 payments — averaging $35.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$512
  • Nevro Corp.$481
  • Medtronic$157
  • Abbott$154
  • Nalu Medical, Inc.$135
  • Pfizer$128
  • plus $359 from 10 others

What the payments were for

  • Food & beverage$1,90799%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,927 in reported general payments places this provider in the 45th percentile of 139 pain medicine providers in Michigan.

See all pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$80,198
Medicare patients
385
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate25$10,117
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen280$4,476
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen160$3,267
Diclofenac Sodium66$1,943
Lidocaine27$1,861
Gabapentin169$1,675
Pregabalin151$1,666
Tizanidine Hcl86$867
Cyclobenzaprine Hcl100$487
Duloxetine Hcl58$486
Naproxen33$307
Baclofen25$302
Lidocaine-PrilocaineLidocaine/Prilocaine19$292
Amitriptyline Hcl51$279
Methocarbamol20$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$96$10,11725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 139 pain medicine providers in Michigan.

Other pain medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →